Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
127.23
+2.93 (+2.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
9,381,891
Open
125.22
Bid (Size)
127.20 (100)
Ask (Size)
127.80 (100)
Prev. Close
124.30
Today's Range
124.14 - 128.18
52wk Range
104.46 - 157.29
Shares Outstanding
1,253,809,440
Dividend Yield
2.58%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
June 15, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
June 12, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Performance
YTD
+4.6%
+4.6%
1 Month
-1.9%
-1.9%
3 Month
-11.9%
-11.9%
6 Month
+7.1%
+7.1%
1 Year
+14.8%
+14.8%
More News
Read More
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
June 11, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
↗
June 09, 2026
Via
Benzinga
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health
↗
May 19, 2026
Via
Chartmill
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 08, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 08, 2026
From
Merck & Co., Inc.
Via
Business Wire
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
↗
June 08, 2026
Via
MarketBeat
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
↗
June 05, 2026
Via
MarketBeat
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
June 05, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
June 04, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
↗
June 04, 2026
Via
The Motley Fool
Topics
ETFs
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
↗
June 02, 2026
Via
Benzinga
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
June 02, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
↗
June 01, 2026
Via
Benzinga
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
↗
May 29, 2026
Via
The Motley Fool
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
May 27, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today
↗
May 26, 2026
Via
Benzinga
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
↗
May 24, 2026
Via
MarketBeat
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
May 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
May 22, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
May 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
May 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
May 21, 2026
From
Gilead Sciences, Inc.
Via
Business Wire
Compugen Q1 Earnings Call Highlights
↗
May 18, 2026
Via
MarketBeat
Topics
Earnings
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 127.23
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/16/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 159.52B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 160B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.